Statistical Techniques | Statistical Mechanics. Get help, support, and tutorials for Windows products—Windows 10, Windows 8.1, Windows 7, and Windows 10 Mobile. In. Play from Briefing. Theravance calls for redemption of $1. Convertible Subordinated Notes due 2. THRX) : Co announced that it has called for redemption all of its outstanding 3% Convertible Subordinated Notes due 2.
Notes. Any 2. 01. Notes outstanding on July 5, 2. The 2. 01. 5 Notes are convertible at any time prior to 5: 0. Eastern time on July 3, 2. Theravance's common stock at a conversion rate of 3. On June 3, 2. 01. Theravance's common stock was $3. Air Lease announces the placement of two new ATR 7. Golden Myanmar Airlines (AL) : 4: 3. Territorial Bancorp adopts fourth repurchase program of 5. TBNK) : Co announces that its Board of Directors has adopted a fourth stock repurchase program. Under this repurchase program, the Company may repurchase up to 5. AVEO Pharma announces strategic restructuring; does not expect tivozanib to receive FDA approval; to hold conference call at 8: 3. ET on Wednesday, June 5 (AVEO) : Co announced a strategic restructuring that will refocus the company's efforts and resources on the ongoing clinical development of tivozanib in colorectal and breast cancer, as well as advancing key pipeline and preclinical assets. This restructuring is expected to extend the company's cash runway for at least two years, which is beyond anticipated data read- outs from ongoing trials of tivozanib and AV- 2. The AVEO management team will host a conference call at 8: 3. ET on Wednesday, June 5 to discuss the restructuring and strategic direction of the company in more detail. As a result of the recent ODAC meeting, we believe that it is likely that tivozanib will not receive FDA approval for renal cell carcinoma or RCC," said William J. Slichenmyer, M. D., chief medical officer of AVEO. With the decision of our partner, Astellas, not to proceed with a European filing for tivozanib or financially support future clinical trials in RCC, AVEO has no plans at this time to pursue tivozanib development in RCC. We deeply regret the impact that this decision may have on the RCC community and wish to express our sincere gratitude to the patients and their families, investigators and nurses who have participated in our trials and supported the development of tivozanib in RCC. Tivozanib will continue to be available to those patients who remain on therapy." "The company intends to focus its R& D efforts on areas in oncology where the unique insights derived from AVEO's proprietary Human Response Platform will allow the development of targeted agents with the potential to provide substantial clinical benefit for specific biomarker- defined patient populations that could enable a clear regulatory pathway to approval," said Tuan Ha- Ngoc, president and chief executive officer of AVEO. Development update: AVEO and Astellas are continuing the BATON Phase 2 clinical trials of tivozanib in breast and colorectal cancer. AVEO intends to continue the development of AV- 2. ERBB3 (HER3) inhibitory antibody candidate, currently in Phase 1 with expansion cohorts in specific biomarker- defined patient populations. As previously announced, the company intends to focus its efforts on further ficlatuzumab development through external collaborations at this time. Ficlatuzumab is a potent hepatocyte growth factor (: HGF) inhibitory antibody that blocks the HGF/c- Met pathway by binding to the HGF ligand with high affinity and specificity. Restructuring and Reogranization: AVEO's strategic restructuring will eliminate approximately 1. AVEO's workforce, across the company. Separately, Elan Ezickson, executive vice president and chief operating officer of AVEO, has informed the company that after a transition period, he will resign effective July 3. Updated Financial Guidance: AVEO ended the first quarter of 2. Based on its revised operating plans, AVEO expects to realize cost reductions of approximately $1. With this restructuring, AVEO expects that its current cash and marketable securities are sufficient to fund operations for at least two years. Marketaxess announces monthly volume statistics for May 2. MKTX) : Co announced total monthly trading volume for May 2. U. S. high- grade volume, $1. This data can be accessed on Market. Axess' website at www. Mitcham Ind misses by $0. MIND) : Reports Q1 (Apr) earnings of $0. Capital IQ Consensus Estimate of $0. Exa beats by $0. 0. Q2 revs in- line; reaffirms FY1. EXA) : Reports Q1 (Apr) adj. Capital IQ Consensus Estimate of ($0. License revenue was $1. Project revenue was $1. Co issues in- line guidance for Q2, sees Q2 revs of $1. Capital IQ Consensus Estimate. Non- GAAP net loss is expected to be in the range of ($0. Co reaffirms guidance for FY1. FY1. 4 revs of $5. Capital IQ Consensus Estimate. Non- GAAP net income is expected to be in the range of $0. Revenue in the first quarter was at the high end of our guidance, increasing 1. With the return of customer spending materializing, we are beginning to see the results of investments that we made over the last several quarters in our field organization. We are particularly encouraged by the strong growth of 4. While certain vertical markets and geographies continue to face economic challenges, overall we have seen an improvement in product development activity among our customer base. With simulation solutions that can replace the need for costly prototypes, we remain confident in our ability to see sequential improvements in year- over- year top line growth as we progress through the remainder of fiscal 2. OCZ Tech announces settlement of shareholder derivative litigation (OCZ) : Co announces that it has reached a settlement in principle of federal shareholder derivative litigation filed in connection with the Company's previously announced financial restatement. The settlement is subject to negotiation of final documentation. It is also subject to court approval. The settlement will be funded by the Company's D& O liability insurance and will not require any payments by the Company. This settlement does not resolve separate consolidated shareholder class actions pending in connection with the restatement. Saba Software: NASDAQ announced it will delist the common stock of Saba Software and Wireless Ronin Technologies (RNIN) (SABA) : NASDAQ announced that it will delist the common stock of Saba Software. Saba Software's stock was suspended on April 0. NASDAQ since that time. Also, NASDAQ announced that it will delist the common stock of Wireless Ronin Technologies (RNIN). Wireless Ronin Technologies' stock was suspended on May 3. NASDAQ since that time. Bazaarvoice beats by $0. BV) : Reports Q4 (Apr) loss of $0. Capital IQ Consensus Estimate of ($0. Fidelity Southern announces $6. LION) : The co intends to use the net proceeds from this offering, together with its cash on hand as necessary, to: (i) redeem the $4. Fixed Rate Cumulative Perpetual Preferred Stock, Series A, originally issued to the U. S. Department of the Treasury under the Troubled Asset Relief Program Capital Purchase Program; and (ii) redeem the two series of its fixed rate trust preferred securities with an aggregate outstanding principal amount of $2. The co intends to use any remaining net proceeds for general corporate purposes. Keefe, Bruyette & Woods, a Stifel company, and Robert W. Baird & Co. are the joint book- running managers in the offering. FIG Partners is acting as co- manager for the offering. Ambarella beats by $0. AMBA) : Reports Q1 (Apr) earnings of $0. Capital IQ Consensus Estimate of $0. Gross margin on a non- GAAP basis for the first quarter of fiscal 2. Co states, "During the quarter, we made excellent progress in the IP security camera market with new design wins at both professional and consumer IP- camera customers. We also saw especially strong revenue growth in the wearable sports camera category, led by market leader Go. Pro. In the automotive camera after- market, we continued to grow revenue while successfully expanding our customer base."4: 0. Atwood Oceanics announces contract for the Atwood Condor (ATW) : Co announced today that one of its subsidiaries has been awarded a drilling services contract by Shell Offshore Inc. Atwood Condor. The contract has a term of 3. Hess Corporation, which is expected to occur in late August 2. The drilling program will be performed in the U. S. Gulf of Mexico at a dayrate of approximately $5. This contract will supersede the remainder of the existing contract with Hess Corporation. With the award of this contract, the firm contractual commitment for the Atwood Condor is expected to extend to November 2.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
November 2017
Categories |